A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Qamra, Amit
- A Review of Digestive Enzyme and Probiotic Supplementation for Functional Gastrointestinal Disorders
Authors
1 Yatharth Super Speciality Hospital, Greater Noida, IN
2 Senior Consultant, Internal Medicine, Bhopal, IN
3 Sunflower Medical Centre, Lucknow, IN
4 Paras Hospitals, Gurugram, IN
5 Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, IN
6 Centre for Clinical Research and Practice & Research Centre for Diabetes, Hypertension and Obesity, Samastipur, IN
Source
The Indian Practitioner, Vol 73, No 3 (2020), Pagination: 35-39Abstract
Functional gastrointestinal disorders (FGIDs) also known as disorders of gut-brain interaction are chronic, recurrent disorders with no identifiable underlying pathology. The FGID with upper abdominal pain and discomfort is the hallmark feature of functional dyspepsia. Around 11-30 % prevalence of functional dyspepsia is reported worldwide. One of the unique features of functional dyspepsia is transient deficiency of digestive enzymes in the system. Digestive enzymes are produced and secreted by the gastrointestinal system to break down fats, proteins, and carbohydrates, to accomplish digestion and, afterwards, the absorption of nutrients. Supplementation with digestive enzymes could provide management of disorders caused by impaired digestive function. Various formulations of enzyme supplementation are available commercially in the market, and are currently used in clinical practice for the management of several digestive diseases. Probiotics have multi-faceted role, helping to restore the gut microbiota.
This review elaborates the potential of multi digestive enzymes along with probiotics in the management of digestive diseases and dyspepsia.
Keywords
Digestive enzyme, Probiotics, Functional Dyspepsia, Indigestion.References
- Stanghellini V. Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV. Dig Dis 2017; 35 (suppl 1):14-17
- Chandran S, et al. A review of functional gastrointestinal disorders: A primer for mental health professionals. Arch Ment Health. 2018; 19:70-81.
- Drossman DA. The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology. 2006; 130(5):1377-90.
- Mearin F, Calleja JL. Defining functional dyspepsia. Rev Esp Enferm Dig. 2011; 103(12):640-7.
- Talley NJ, Ford AC. Functional Dyspepsia. N Engl J Med. 2015; 373(19):1853-63.
- Ghoshal UC, Singh R. Functional dyspepsia: the Indian scenario. J Assoc Physicians India. 2012 Mar; 60 Suppl:6-8.
- Mahadeva S, Goh KL. Epidemiology of functional dyspepsia: A global perspective. World J Gastroenterol. 2006; 12(17):2661-6.
- Talley NJ et al. Guidelines for the management of dyspepsia. Am J Gastroenterol. 2005 Oct; 100(10):2324-37.
- GianlucaIaniro et al. Digestive Enzyme Supplementation in Gastrointestinal Diseases. Curr Drug Metab. 2016 Feb; 17(2): 187-193.
- Swami OC, Shah N. Functional dyspepsia and the role of digestive enzymes supplement in its therapy. Int J Basic Clin Pharmacol. 2017 May; 6(5):1035-1041
- Laugier R, Bernard JP, Berthezene P, Dupuy P. Changes in pancreatic exocrine secretion with age: pancreatic exocrine secretion does decrease in the elderly. Digestion. 1991; 50(3-4):202-11.
- Feldman M, Cryer B, McArthur K, Huet BA, Lee E. Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study. Gastroenterology. 1996; 110(4):1043-52.
- Madisch A, et al. The Diagnosis and Treatment of Functional Dyspepsia. Dtsch Arztebl Int. 2018 Mar; 115(13): 222-232.
- Samsom M, Verhagen MA, Van Berge H, Smout AJ. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology. 1999; 116(3):515-20.
- Kusunoki H, Haruma K, Manabe N, Imamura H, Kamada T, Shiotani A, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neuro gastroenterol Motil. 2012; 24(6):540-5.
- Du LJ, Chen BR, Kim JJ, Shen JH, Dai N. Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis. World J Gastroenterol. 2016; 22(12):3486-95.
- Banka N, Sawant P, Vartak M, Pawar D. Efficacy and Tolerability of Unienzyme MPS-A Multienzyme Preparation with Simethicone in Patients with Nonulcer, Dyspepsia. Indian Medical Gazette. 2001; 135(7):294-305.
- Khandke DA, Shirsath PA, Jain SK. Post-Marketing Surveillance Study to Assess the Efficacy and Tolerability of Al5zyme-A Multienzyme Preparation in Patients with Functional Dyspepsia. Indian Medical Gazette. 2013; 181-91.
- O’Toole PW, Cooney JC. Probiotic bacteria influence the composition and function of the intestinal microbiota. Interdiscip Perspect Infect Dis. 2008; 2008():175-285.
- Hemarajata P, Versalovic J. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therap Adv Gastroenterol. 2013 Jan; 6(1): 39-51.
- GianlucaIaniro et al. Digestive Enzyme Supplementation in Gastrointestinal Diseases. Curr Drug Metab. 2016 Feb; 17(2): 187-193.
- Gut reaction: A limited role for digestive enzyme supplements. Available on: https://www.health.harvard.edu/staying-healthy/gut-reaction-a-limited-role-for-digestive-enzyme-supplements
- Pawar D. Efficacy and Tolerability of Unienzyme MPS-A Multienzyme Preparation with Simethicone in Patients with Non-ulcer, Dyspepsia. Indian Medical Gazette. 2001; 135(7):294-305.
- Khandke D et al. Post-Marketing Surveillance Study to Assess the Efficacy and Tolerability of Al5zyme-A Multienzyme Preparation in Patients with Functional Dyspepsia. Indian Medical Gazette. 2013; 181-91.
- Ahyani T. Lactobacillus probiotics for treating functional dyspepsia in children. Paediatrica Indonesiana. 2016; 56(1):37-42.
- Ivermectin in Covid-19: Review of the Current Evidence
Authors
1 Senior Director and Head, BLK Centre for Chest & Respiratory diseases, BLK Super Speciality Hospital, New Delhi, IN
2 Senior Consultant and Head, Department of Interventional Pulmonology, Respiratory & Sleep Medicine, Manipal Hospitals, New Delhi, IN
3 Senior Consultant, Critical Care & Internal Medicine, Fortis Escorts Hospital, Jaipur, IN
4 Senior Consultant & Head- Internal Medicine & Diabetology. Yatharth Super Speciality Hospital, Greater Noida, IN
5 Consultant, Institute of Critical Care Medicine, Sir Ganga Ram Hospital, New Delhi, IN
6 Senior Consulting Physician, Arpan Sugar Clinic, Bilaspur, IN
7 Department of Pulmonary Medicine, AIIMS, Raipur, IN
8 Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, IN
Source
The Indian Practitioner, Vol 74, No 3 (2021), Pagination: 27-33Abstract
The COVID‑19 pandemic has gripped the world in fear with more than 109 million cases and more than 2.4 million deaths as of 16th February 2021. After US, India has the second highest number of cases in the world. A pandemic of this scale has clearly become an unmet medical need warranting research on effective pharmaco-therapeutic agents. Given the time constraints, existing drugs have been repurposed to fill in the gap. Ivermectin is an FDA-approved broad spectrum antiparasitic agent. It is enlisted in the core list of WHO Model List of Essential Medicine 2019. Ivermectin is economical, easily available and safe without any major side effects. Recent research has shown that Ivermectin possesses strong anti-viral properties. It can also be safely combined with other repurposed drugs for Covid-19. Here, we review mechanism of action and current scientific evidence of Ivermectin in treatment and prophylaxis of Covid-19. A number of ongoing clinical trials are evaluating the drug further in the treatment and prophylaxis of Covid-19. Based on the current clinical evidence in treatment and prophylaxis, Indian Experts’ consensus and recommendations by multiple Indian state governments, Ivermectin may effectively and safely add to the current armamentarium of Indian clinicians involved in the care and management of Covid-19 patients.Keywords
Ivermectin, Covid-19. SARS-CoV-2.References
- Worldometer [Internet]. Coronavirus. [cited 2021 Feb 16]. Available from https://www.worldometers.info/coronavirus/
- Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, Hosein Z, Padda I, Mangat J, Altaf M. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med. 2020 Jun 25:1-8.
- Ministry of Health and Family Welfare, Government of India [Internet]. Covid 19 Vaccination Status. [cited 2021 Feb 16]. Available from https://www.mohfw.gov.in/.
- Financial Express [Internet]. Covid-19 vaccine rollout: India approves Covaxin, Covishield; what next?. 2021 Jan 5. [cited 2021 Feb 16]. Available from https://www.financialexpress.com/lifestyle/health/covid-19-vaccine-rollout-india-approves-covaxin-covishield-what-next/2164444/
- Long L, Wu L, Chen L, Zhou D, Wu H, Lu D, et al. (2021) Effect of early oxygen therapy and antiviral treatment on disease progression in patients with COVID-19: A retrospective study of medical charts in China. PLoS Negl Trop Dis 15(1): e0009051.
- Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK. Drug repurposing approach to fight COVID-19. Pharmacol Rep. 2020 Dec;72(6):1479-1508.
- Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 May 12;323(18):1824-1836.
- Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. Clinical Management Protocol: COVID-19 [Internet]. Version 5. 2020 July 3 [cited 2020 Oct 20]. Available from https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated03072020.pdf
- Alanagreh L, Alzoughool F, Atoum M. The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms. Pathogens. 2020 Apr 29;9(5):331.
- Al-Kuraishy HM, Hussien NR, Al-Naimi MS, Al-Buhadily AK, Al-Gareeb AI, Lungnier C. Is ivermectin–Azithromycin combination the next step for COVID-19?. Biomed Biotechnol Res J 2020;4, Suppl S1:101-3
- Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020 Apr 16;181(2):281-292.e6.
- Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020 May;581(7807):215-20.
- Banerjee K, Nandy M, Dalai CK, Ahmed SN. The Battle against COVID 19 Pandemic: What we Need to Know Before we “Test Fire” Ivermectin. Drug Res (Stuttg). 2020 Aug;70(8):337-40.
- Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787.
- Vora A, Arora VK, Behera D, Tripathy SK. White paper on Ivermectin as a potential therapy for COVID-19. Indian J Tuberc. 2020 Jul;67(3):448-51.
- Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest. 2021 Jan;159(1):85-92.
- Gorial FI, Mashhadani S, Sayaly HM, Dakhil BD, Al Mashhadani MM, Aljabory AM, Abbas HM, Ghanim M, Rasheed JI. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial) [Preprint]. medRxiv 2020.07.07.20145979. Available from https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1
- Podder S, Chowdhury N, Sina M, Ul Haque W. Outcome of ivermectin treated mild to moderate COVID-19 cases: a single centre, open-label, randomized controlled study. IMC J Med Sci 2020; 14 (2): 002.
- Chowdhury ATMM, Shahbaz M, Karim MR, Islam J, Guo D, He S. A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients [preprint]. medRxiv 2020.07.07.20145979. Available from https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1
- Rahman MA, Iqbal S, Islam MA, Niaz MK, Hussain T, Siddiquee T. Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients. Journal of Bangladesh College of Physicians and Surgeons. 2020;38:5-9.
- Alam MT, Murshed R, Bhiuyan E, Saber S, Alam R, Robin R. A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. Journal of Bangladesh College of Physicians and Surgeons. 2020;38:10-15.
- Behera P, Patro BK, Singh AK, Chandanshive PD, S R R, Pradhan SK, Pentapati SSK, Batmanabane G, Mohapatra PR, Padhy BM, Bal SK, Singh SR, Mohanty RR. Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study. PLoS One. 2021 Feb 16;16(2):e0247163.
- Directorate of Medical & Health Services, Uttar Pradesh [Internet]. COVID 19 documents. c2021 [cited 2021 Feb 19]. Available from: http://dgmhup.gov.in/DocumentsCovid19/1621.pdf
- Rebamipide in Recurrent Aphthous Stomatitis: Review of Indian Evidence
Authors
1 Department Otorhinolaryngology and Head and Neck Surgery, MAA ENT Hospital, Hyderabad, IN
2 Department of Oral Medicine and Radiology, Faculty of Dentistry, Jamia Millia Islamia, New Delhi, IN
3 Department of ENT, Trustwell Hospitals, Bangalore, IN
4 Department of ENT, Jagtap Hospital, Dhule, IN
5 Department of Internal Medicine & Diabetology, Yatharth Super Speciality Hospital, Greater Noida, IN
6 Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, IN
Source
The Indian Practitioner, Vol 74, No 11 (2021), Pagination: 30-35Abstract
Recurrent aphthous stomatitis (RAS) is one of the commonly observed disease of the oral cavity and the prevalence ranges from 5 to 60%. Despite its high prevalence, the exact pathophysiology of the disease remains unknown. Multiple etiologic factors, followed by three stages of the disease, and types based on severity, with addition of pain and inflammation makes the management challenging for the clinician. A number of drugs are available for the treatment having their own advantages and limitations. In this narrative review, we review the available Indian evidence with Rebamipide in RAS. Indian clinical evidence clearly establishes the safety and efficacy of rebamipide in the management of RAS. Thus, considering the benefits of reduced duration of pain, accelerated healing and decreased recurrence, we conclude that the current Indian evidence supported by our clinical experience establishes the role of Rebamipide in RAS. Hence, we recommend Rebamipide may be considered as a first line treatment option in RAS.Keywords
Recurrent Aphthous Stomatitis, Rebamipide.References
- Rivera C. Essentials of recurrent aphthous stomatitis (Review). Biomed Rep. 2019 Aug;11:47-50.
- Altenburg A, El-Haj N, Micheli C, Puttkammer M, Abdel-Naser MB, Zouboulis CC. The treatment of chronic recurrent oral aphthous ulcers, Dtsch Arztebl Int. 2014 Oct;111:665–73.
- Sánchez-Bernal J, Conejero C, Conejero R. Aftosis oral recidivante recurrent Aphthous Stomatitis. Actas Dermo-Sifiliográficas. 2020 Aug;111(6): 471-80.
- Akintoye SO, Greenberg MS. Recurrent Aphthous Stomatitis. Dent Clin North Am. 2014 Apr;58(2):281–97.
- Karambelkar MV, Ashwinirani SR, Sande A, Kamala KA. Comparative study of occurrence of recurrent aphthous sto matitis during exam stress and relaxed phase in dental college students of Krishna Institute of Medical Sciences. BLDE Univ J Health Sci. 2020 Dec;5(2):173-7.
- Tarakji B, Gazal G, Al-Maweri SA, Azzeghaiby SN, Alaizari N. Guideline for the Diagnosis and Treatment of Recurrent Aphthous Stomatitis for Dental Practitioners. J Int Oral Health 2015 May;7(5):74-80.
- Khurshid AM, Nagaraj K. Herpetiform Ulceration Involving Pharynx – Case Report. J Dental Sci. 2017 Oct;2(6):1-3.
- Slezakova S, Linhartova PB, Bartova J, Petanova J, Kuklinek P, Fassmann A, Dusek L, Holla LI. Gene variability in matrix metalloproteinases in patients with recurrent aphthous stomatitis. J Oral Pathol Med. 2020 Mar;49(3):271–77.
- Linhartova PB, Janos J, Slezakova S, Bartova J, Petanova J, Kuklinek P, Fassmann A, Dusek L, Holla LI. Recurrent aphthous stomatitis and gene variability in selected interleukins: a case–control study. Eur J Oral Sci. 2018 Dec;126(6):485-92.
- Parssinen M, Jäsberg H, Mikkonen JJW, Kullaa AM. Oral mucosal pellicle as an immune protection against micro-organisms in patients with recurrent aphthous stomatitis: A hypothesis. Med Hypotheses. 2021 Jan;146:110449.
- Cakir E. Is there any relationship between recurrent oral aphthous stomatitis and prediabetes?. Med Hypotheses. 2013 Sep;81(3):512-3.
- Bagan J, Saez G, Tormos C, Gavalda C, Sanchis JM, Bagan L, Scully C. Oxidative stress and recurrent aphthous stomatitis. Clin Oral Investig. 2014 Nov;18(8):1919-23.
- Aminabadi NA. Recurrent aphthous stomatitis may be initiated by traumatic epithelial implantation and sustained by localized pathergic status. Med Hypotheses. 2008;70(3):522-4.
- Field EA, Allan RB. Oral ulceration – Aetiopathogenesis, Clinical Diagnosis and Management in the Gastrointestinal Clinic. Aliment Pharmacol Ther. 2003 Nov;18(10):949-62.
- Motahari P, Pournagi-Azar F, Khodadadi P. Role of tumor necrosis factor-alpha in pathogenesis of recurrent aphthous stomatitis: A systematic review and meta-analysis. J Oral Health Oral Epidemiol. 2020 Jul;9(3):108-15.
- Archana JP, Prabhakaran AC. Pharmacotherapy of recurrent aphthous ulcers. Chron Young Sci. 2011 Jan;2(3):134-8.
- Vivek V, Nair BJ. Recurrent aphthous stomatitis: current concepts in diagnosis and Management. J Indian Acad Oral Med Radiol. 2011 Jul;23(3):232-36.
- Katz J, Langevitz P, Shemer J, Barak S, Livneh A. Prevention of recurrent aphthous stomatitis with Colchicine: an open trial. J Am Acad Dermatol. 1994 Sep;31(3):459-61.
- Sridhar T, Elumalai M, Karthika B. Recurrent aphthous stomatitis: A review. Biomed Pharmacol J. 2013;6(1):17-22.
- Halboub E, Al-Maweri SA, Parveen S, Al-Wesabi M, Al-Sharani HM, Al-Sharani A, Al-Kamel A, Albashari A, Shamala A. Zinc Supplementation for Prevention and Management of Recurrent Aphthous Stomatitis: A Systematic Review, J Trace Elem Med Bio. 2021 Dec;68:126811.
- Ogino K, Hobara T, Ishiyama H, Yamasaki K, Kobayashi H, Izumi Y, Oka S. Antiulcer mechanism of action of Rebamipide, Anovel antiulcer compound, on DiethyldithiocarbamateInduced antral gastric ulcers in rats. Eur J Pharmacol. 1992 Feb;212(1):9-13.
- Kudur MH, Hulmani M. Rebamipide: A novel agent in the treatment of recurrent aphthous ulcer and Behcet’s Syndrome. Indian J Dermatol. 2013 Oct;58(5):352–54.
- Li W, Zhao Y, Xu X, Ma W, Gao P, Wang Y, Liang K, Li R. Rebamipide suppresses TNF-α mediated inflammation in vitro and attenuates the severity of dermatitis in mice. FEBS J. 2015 Jun;282(12):2317-26.
- Tajima K, Hattori T, Takahashi H, Katahira H, Niramatsu A, Kumakura S, Goto H.Rebamipidesuppresses TNF-α production and macrophage infiltration in the Conjunctiva. Vet Ophthalmol. 2018 Jul;21(4):347-52.
- Naito Y, Yoshikawa T.Rebamipide: Agastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3);261-70.
- Kesavalingam K, Sivakumar V, Meera SS, Karthikeyan T, Vijayanand, Venkateshwar R. A prospective study on efficacy of Rebamipide in recurrent aphthous stomatitis. IOSR Journal of Dental and Medical Sciences. 2017 Oct;16(10):44-5.
- Uppalwar P, Kunjir G, Krishna Kumar R, Chandwani R, Kelgandre D, Donempudi P. Comparison of therapeutic effect of topical Amlexanox (5%), and oral Rebamipide (100 mg) in the management of oral apthousulceration. Journal of Oral and Dental Health. 2016;2(1):6-8.
- Jadhav A, Marathe S, Mhapuskar A, Jadhav S, Thopte S, Vhatakar P. To evaluate the efficacy of Rebamipide on clinical resolution and recurrence of minor recurrent aphthous stomatitis. Int J Dent Health Sci. 2015 Jan;2(4):781-97.
- Parvathi Devi MK, Ramesh DN, Koppal S, Byatnal AR, Rukmangada T, Byatnal AA. Efficacy of Rebamipide and Levamisole in the treatment of patients with recurrent aphthous ulcer - acomparative study. J Clin Diagn Res. 2014 Nov;8(11):ZC119–ZC122.
- Hasan S, Perween N, Saeed S, Mandeep K, Gombra V, Rai A. Evaluation of 5% Amlexenoxoral paste and Rebamipidetablets in treatment of recurrent apthousstomatitis and comparison with Dologel CT. Indian J Otolaryngol Head Neck Surg. 2020 Apr. DOI: doi.org/10.1007/s12070-02001858-1
- Singh A, Adil HA, Umarji HR. Evaluation of the efficacy of topical Amlexanoxoral paste and Rebamipidetablets in the management of recurrent Aphthous Ulcers. Int J Curr Res. 2018 Jul;10(7):71105-8.